Strategic Stocks To Watch CANNABIS SCIENCE INCORPORATED (OTCBB: CBIS)
Up 30.51% on Friday
Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
CBIS News:
January 12 – Generex Biotechnology and Cannabis Science (CBIS) Look to Make Headway in Lucrative Cancer Drug Market
01-17-12 Strategic Stocks To Watch CANNABIS SCIENCE INCORPORATED (OTCBB: CBIS)
Five Star Equities Provides Stock Research on Generex Biotechnology & Cannabis Science
Several small cap biotechnology stocks are looking to make a splash in the highly lucrative cancer drug market this year. According to a recent press release issued by Denver-based Cannabis Science, global cancer drug sales are expected to grow at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion by 2012. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Generex Biotechnology Corporation (OTCBB: GNBT) and Cannabis Science Inc. (OTCBB: CBIS).
Access to the full company reports can be found at:
www.fivestarequities.com/GNBT
www.fivestarequities.com/CBIS
Cannabis Science, Inc. is a development stage company engaged in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. Last week the company reported the continuing successful progress by two patients who have been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer and Skin Cancer.
Cannabis Science recently issued its fiscal 2012 earnings guidance. The company says sales for 2012 are forecasted to be $6,846,000, while arguing that the company’s revenues have “the potential to increase to $65,740,000 in 2014.”
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. The Company’s novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. Positive interim results from the ongoing Phase 2 study of AE37 were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in December. The company says that final Phase 2 results are expected at some point this year.
If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.
Like all investment strategies, trading in stocks involves risk and volatility. Past performance is not an indication of future results. Actual results will be based on a consumer’s individual purchase and sale decisions.
Please read our Disclaimer regards to CBIS or any company reviewed or blogged about at Strategic Penny Stocks.
